Novartis Pharma, Chugai Pharmaceutical to Ship Agent for Postmenopausal Breast Cancer.
The new agent is available for adjuvant treatment of early-stage breast cancer in postmenopausal women as well as primary and secondary care for patients with advanced and recurrent breast cancer.
Femara is currently available in over 90 countries worldwide.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||May 11, 2006|
|Previous Article:||Kissei Pharmaceutical, Daiichi Pharmaceutical Jointly Launch Urination Disorder Improving Drug.|
|Next Article:||Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.|